UniQure's Huntington's therapy fails to significantly slow disease progression in trial

UniQure NASDAQ:QURE, NASDAQ:QURE said on Tuesday its Huntington's treatment showed 44% slowing of disease progression, but did not reach statistical significance in an ongoing early-to-mid-stage trial.U.S.-listed shares of the Dutch gene therapy developer fell 63% in premarket trading.